期刊文献+

载铜绿假单胞菌DNA疫苗温敏水凝胶系统的构建及体内评价 被引量:1

Construction and in vivo evaluation of a thermosensitive hydrogel system loading with Pseudomonas aeruginosa DNA vaccine
下载PDF
导出
摘要 构建载铜绿假单胞菌(Pseudomonas aeruginosa,PA)DNA疫苗的PLGA-PEG-PLGA温敏水凝胶系统,评价该系统的体内免疫效力。通过简单物理混合法制备PA DNA疫苗的PLGA-PEG-PLGA温敏水凝胶,测量其胶凝温度;评价其体外毒性、体外累计释放率;通过凝胶体积变化评价水凝胶的体内降解;将小鼠分为对照组(PBS)、水凝胶组(Hydrogel)、in vivo-jetPEI/质粒DNA组(in vivo-jetPEI/p DNA)、水凝胶+in vivo-jetPEI/质粒DNA组(Gel+in vivo-jetPEI/pDNA),免疫3次,每次间隔10 d,末次免疫2周后处死小鼠,检测血清特异性IgG抗体、脾淋巴细胞增殖情况及细胞上清液中IFN-γ水平。结果显示,PLGA-PEG-PLGA水凝胶具有温敏性,相变温度为(32±0.5)℃;体外对DC 2.4细胞无明显毒性;体外释放7 d时约释放80%的质粒DNA;PLGA-PEG-PLGA在体内具有可降解性,大约15 d几乎完全降解;体内免疫实验表明in vivo-jetPEI/pDNA及Gel+in vivo-jetPEI/pDNA组小鼠脾淋巴细胞明显增殖、特异性IgG抗体及IFN-γ水平升高,且水凝胶可增强DNA疫苗诱导的免疫反应水平。结果表明,载PA DNA疫苗的温敏水凝胶系统是研发PA疫苗有前景的一种新策略。 A thermosensitive hydrogel system consisting of PLGA-PEG-PLGA hydrogel and Pseudomonas aeru⁃ginosa DNA vaccine was constructed and the immune efficacy of the system was evaluated.The PLGA-PEGPLGA thermosensitive hydrogel containing Pseudomonas aeruginosa DNA vaccine was prepared by a simple physical mixing method.The gelation temperature,cytotoxicity,and release curve in vitro were tested.The degradability of hydrogel in vivo was evaluated.The mice were divided into control group(PBS),hydrogel group(Hydrogel),in vivo-jetPEI/plasmid DNA group(in vivo-jetPEI/pDNA),and hydrogel+in vivo-jetPEI/plasmid group(Gel+in vivo-jetPEI/pDNA).Mice were immunized three times with a ten-day interval.Two weeks after the last immunization,the mice were sacrificed.The proliferation of splenic lymphocytes,serum specific IgG anti⁃bodies and IFN-γin supernatant of splenic lymphocytes were detected.The gelation temperature of PLGA-PEGPLGA hydrogel was(32±0.5)℃.There was no obvious toxicity to cells in vitro,and about 80%of plasmid DNA was released after 7 days in vitro.PLGA-PEG-PLGA hydrogel was biodegradable,and degraded almost completely after 15 days in vivo.The spleen lymphocytes proliferated;the levels of specific IgG antibodies and IFN-γof in vivo-jetPEI/pDNA and Gel+in vivo-jetPEI/pDNA groups increased.The hydrogel could enhance the immune response induced by DNA vaccine.Results suggest that the thermosensitive hydrogel system consisting of PLGA-PEG-PLGA hydrogel and Pseudomonas aeruginosa DNA vaccine is a promising new strategy for the development of PA vaccine.
作者 石敏 雍琴 何颖娜 黄仕琴 赵轩 余娴 SHI Min;YONG Qin;HE Yingna;HUANG Shiqin;ZHAO Xuan;YU Xian(Phase I Clinical Trial Center,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010;College of Pharmacy,Hebei University of Chinese Medicine,Shijiazhuang 050200;Department of Pharmacy,Central Hospital of Jiangjin District,Chongqing 402260,China)
出处 《中国药科大学学报》 CAS CSCD 北大核心 2021年第2期186-194,共9页 Journal of China Pharmaceutical University
基金 国家自然科学基金资助项目(No.82072327) 重庆市卫生计生委重点项目资助(No.2016ZDXM010)。
关键词 PLGA-PEG-PLGA 温敏水凝胶 铜绿假单胞菌 DNA疫苗 免疫 PLGA-PEG-PLGA thermosensitive hydrogel Pseudomonas aeruginosa DNA vaccine immune
  • 相关文献

参考文献2

二级参考文献36

  • 1Goldring M B, Goldring S R.Osteoarthritis.Journal of Cellular Physiology, 2007, 213, 626-634.
  • 2Wieland H A, Michaelis M, Kirschbaum B J, Rudolphi K A.Osteoarthritis-an untreatable disease? Nature Reviews Drug Discovery, 2005, 4, 331-344.
  • 3Vavken P, Dorotka R.Burden of musculoskeletal disease and its determination by urbanicity, socioeconomic status, age, and sex: Results from 14,507 subjects.Arthritis Care & Research, 2011, 63, 1558-1564.
  • 4Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D.Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment.European Journal of Pain, 2006, 10, 287-333.
  • 5Loza E, Abasolo L, Jover J A, Carmona L.Burden of disease across chronic diseases: A health survey that measured prevalence, function, and quality of life.The Journal of Rheumatology, 2008, 35, 159-165.
  • 6Conaghan P G, Kloppenburg M, Schett G, Bijlsma J W.Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee.Annals of the Rheumatic Diseases, 2014, 73, 1442-1445.
  • 7Loza E, Lopez-Gomez J M, Abasolo L, Maese J, Carmona L, Batlle-Gualda E.Economic burden of knee and hip os-teoarthritis in Spain.Arthritis and Rheumatism, 2009, 61, 158-165.
  • 8Jevsevar D S.Treatment of osteoarthritis of the knee: evi-dence-based guideline, 2nd edition.Journal of the American Academy of Orthopaedic Surgeons, 2013, 21, 571-576.
  • 9Fernandes L, Hagen K B, Bijlsma J W J, Andreassen O, Christensen P, Conaghan P G, Doherty M, Geenen R, Hammond A, Kjeken I, Lohmander L S, Lund H, Mallen C D, Nava T, Oliver S, Pavelka K, Pitsillidou I, da Silva J A, de la Torre J, Zanoli G, Vliet Vlieland T P M.EULAR recom-mendations for the non-pharmacological core management of hip and knee osteoarthritis.Annals of the Rheumatic Diseases, 2013, 72, 1125-1135.
  • 10Bijlsma J W, Berenbaum F, Lafeber F P.Osteoarthritis: An update with relevance for clinical practice.Lancet, 2011, 377, 2115-2126.

共引文献5

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部